AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00710047
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one single 10mg dose
Trial: NCT03790176
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
Trial: NCT00628732
Drug: Cyclophosphamide and Topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
Trial: NCT00006054
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006054
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00198445
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop in study eye every 12 hours for 14 days
Trial: NCT00198445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in study eye every 12 hours for 14 days
Trial: NCT00208312
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.14 mg/kg/min for 6 minutes, intravenous infusion
Trial: NCT03553433
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
Trial: NCT01290133
Drug: GW597599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose IV infusion
Trial: NCT01290133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose IV infusion
Trial: NCT03054467
Drug: Caduet 10Mg-20Mg Tablet
RxNorm normalized name: Caduet 10mg-20mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
Trial: NCT03054467
Drug: NorvasC® 10 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
Trial: NCT00796601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablets (0 mg esreboxetine), once daily for 6 months
Trial: NCT02779192
Drug: SPI-1005 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
Trial: NCT02779192
Drug: SPI-1005 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
Trial: NCT02779192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
Trial: NCT00389740
Drug: MK0217, /Duration of Treatment : 12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03745196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT00832546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00832546
Drug: Oral NGX426 (Powder in solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03414008
Drug: Matching placebo: Tartaric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00669916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single infusion of placebo
Trial: NCT01054820
Drug: FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
Trial: NCT01788306
Drug: OOPEN+BBCC
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
Trial: NCT02624973
Drug: Neoadjuvant docetaxel + cyclophosphamide
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02624973
Drug: Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02624973
Drug: Adjuvant Epirubicin+ Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02605954
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Trial: NCT02605954
Drug: ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/300 mg tablets administered orally once daily
Trial: NCT02605954
Drug: Third Antiretroviral Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG
Trial: NCT04609254
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
Trial: NCT02301143
Drug: Chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02301143
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00803647
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
Trial: NCT02385448
Drug: Microgynon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
Trial: NCT02148250
Drug: U-500 insulin, 100 syringe units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
Trial: NCT02148250
Drug: U-500 insulin, 200 syringe units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
Trial: NCT02553330
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00373334
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02896855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Trial: NCT02370602
Drug: [^11C]T-773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[\^11C\]T-773 IV solution
Trial: NCT00354523
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.
Trial: NCT01571362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo, divided into symmetric doses and administered twice daily
Trial: NCT04547894
Drug: ASC09F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
Trial: NCT02529774
Drug: Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1
Trial: NCT02529774
Drug: Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1
Trial: NCT03222518
Drug: paracetamol-NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
Trial: NCT04501679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received matching placebo as SC injection.
Trial: NCT03417687
Drug: 129Xe MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of pulmonary function
Trial: NCT03417687
Drug: 133 Xe scintigraphy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of pulmonary function
Trial: NCT04137380
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04137380
Drug: Placebo - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02777151
Drug: REGN3470-3471-3479
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02777151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03667053
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for dasiglucagon
Trial: NCT00041132
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 on days 2-4 of cycles 1,3,5,7
Trial: NCT01621217
Drug: 5-Fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be given intravenously twice together with Mitomycin C during study treatment
Trial: NCT03455972
Drug: Immunomodulatory drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy
Trial: NCT00990223
Drug: Eplerenone or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 100 mg or Placebo, daily for 10 days.
Trial: NCT00041132
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7
Trial: NCT00041132
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 170 mg over days 3-5 of cycles 2,4,6,8
Trial: NCT00041132
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8
Trial: NCT02907021
Drug: standard-of-care treatments for LV impairment
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
Trial: NCT03997851
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acetaminophen gel
Trial: NCT02073084
Drug: K-877 Low Dose
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 Low Dose
Trial: NCT02073084
Drug: K-877 High Dose
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 High Dose
Trial: NCT00782340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Trial: NCT01362140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection every 3 weeks
Trial: NCT03446443
Drug: Honghe Fujie lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
Trial: NCT02428868
Drug: intravenous iron (Ferroven®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
Trial: NCT01265069
Drug: concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
Trial: NCT00250887
Drug: Gefitnib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01357798
Drug: 0,9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
Trial: NCT03793985
Drug: R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D086 and D337 co-administration
Trial: NCT03560427
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
Trial: NCT02415400
Drug: vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02415400
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00395876
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Trial: NCT00604253
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05216172
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active drug
Trial: NCT05216172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03564912
Drug: Capecitabine Oral Tablet [Xeloda]
RxNorm normalized name: capecitabine Oral Tablet [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
Trial: NCT00167544
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
Trial: NCT00167544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT00126516
Drug: Angiotensin-converting Enzyme Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any dosage, frequency, and duration
Trial: NCT04458948
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 mg, IV or po for 5 days
Trial: NCT02440958
Drug: modified FOLFIRINOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
Trial: NCT00868023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00647868
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
Trial: NCT03719326
Drug: Pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
Trial: NCT00875836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dose, up to 60 mg daily
Trial: NCT01140191
Drug: WR 279,396
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
Trial: NCT00549926
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00549926
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00981591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
Trial: NCT03095521
Drug: ANTI-ANGIN® FORMULA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution.
Trial: NCT00755846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
Trial: NCT01711320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03444818
Drug: [14C]-E6007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00124527
Drug: Irofulven + capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01650259
Drug: OAD
RxNorm normalized name: Toad toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAD except Trazenta tablets
Trial: NCT02389712
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed \> 40mg.
Trial: NCT00444509
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
Trial: NCT03349450
Drug: Cyclophosphamide 50mg
RxNorm normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
Trial: NCT00936858
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no